Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | TNIK | Q9UKE5 | 7/20 | 0.41 |
| ▸ | TTBK1 | Q5TCY1 | 4/20 | 0.38 |
| ▸ | CHUK | O15111 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17036514 | 0.85 | GRM5 (0.50) | GRM5KMT2AATM | |
| SCHEMBL18034675 | 0.79 | TTBK1 (0.43) | TTBK1CHUKPAK4 | |
| SCHEMBL25486882 | 0.79 | TTBK1 (0.38) | TTBK1CHUKKMT2AATM | |
| SCHEMBL4520127 | 0.79 | TTBK1 (0.38) | TTBK1CHUKKMT2AATM | |
| SCHEMBL8972795 | 0.79 | TTBK1 (0.38) | TNIKTTBK1CHUKKMT2A | |
| SCHEMBL17039215 | 0.75 | GRM5 (0.54) | GRM5 | |
| SCHEMBL700507 | 0.75 | HTT (0.46) | GRM5TNIKKMT2AATM | |
| SCHEMBL16673635 | 0.75 | P4HA1 (0.46) | GRM5 | |
| SCHEMBL4521359 | 0.73 | MCHR1 (0.42) | TNIKCHUK | |
| SCHEMBL12750896 | 0.72 | GRM5 (0.50) | GRM5TNIKTTBK1CHUKKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1847545-B1 | SUBSTITUTED ETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | UBE INDUSTRIES (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-8137821-B2 | Substituted ethynyl gold-nitrogen containing heterocyclic carbene complex and organic electroluminescent device using the same | UBE INDUSTRIES, LTD. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090091243-A1 | Substituted Ethynyl Gold-Nitrogen Containing Heterocyclic Carbene Complex and Organic Electroluminescent Device Using the Same | UBE INDUSTRIES, LTD. (JP) | 2009-04-09 | — | — | US | disclosed |
| EP-1847545-A1 | SUBSTITUTED ETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | Ube Industries, Ltd. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090091243-A1 | Substituted Ethynyl Gold-Nitrogen Containing Heterocyclic Carbene Complex and Organic Electroluminescent Device Using the Same | ACSL3, ATXN2L, ACSL1 | GRM5 1297/4885TNIK 1727/4885TTBK1 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.